Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trafermin in neuropathic diabetic foot ulcers
NCT01217476Phase 3Completed
- Sponsor
- Olympus Biotech
- Start
- Dec 2010
- Primary completion
- May 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of trafermin in diabetic foot ulcer (DFU), sponsored by Olympus Biotech. Primary endpoint: Wound Closure Rate of Diabetic Foot Ulcers at 12 weeks. Started Dec 2010; status: completed.
02
Drugs
trafermin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT01217476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217476.